Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, announced the acquisition of Novaestiq Corp. by Waldencast plc. Novaestiq, a joint venture between Croma-Pharma and Gore Range Capital, is the company behind the innovative Saypha ChIQ and Saypha MagIQ injectable hyaluronic acid gels, which are set to launch in the U.S. under the Obagi Medical brand.
This transaction marks a key milestone in Croma-Pharma's international growth strategy and reinforces its commitment to providing scientifically validated, high-quality products for the global aesthetic market.
"We are thrilled to see Novaestiq join forces with Waldencast, a move that amplifies our shared commitment to advancing aesthetic medicine," said Andreas Prinz, CEO of Croma-Pharma GmbH. "The introduction of Saypha ChIQ and MagIQ to the U.S. market under the Obagi Medical brand marks a significant step in delivering innovative, science-driven aesthetic solutions to patients worldwide."
Saypha, developed and manufactured by Croma-Pharma, is a globally recognized line of hyaluronic acid (HA) injectables known for their safety, efficacy, and high patient satisfaction. With over 40 years of experience in HA products, Croma-Pharma has produced more than 110 million syringes to date, and its fillers are approved in over 80 markets worldwide. The company maintains a dedicated focus on aesthetic medicine and offers a broad portfolio of minimally invasive treatments.
The upcoming U.S. launch of Saypha injectables, currently undergoing the FDA approval process, is supported by a robust clinical program, including pivotal studies that exceed industry standards in size and diversity. These trials reflect Obagi Medical's and Croma-Pharma's shared commitment to inclusivity and scientific excellence in aesthetic care.
"This partnership is a testament to the strength of our innovation pipeline and our ability to collaborate with visionary partners," added Prinz. "We are confident that Waldencast and Obagi Medical will successfully bring Saypha® to a new generation of U.S. physicians and patients."
Comments powered by CComment